| Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod 8:18am / Zacks.com - Paid Partner Content | Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205 Jun 19 / Zacks.com - Paid Partner Content |
| Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger Jun 22 / Zacks.com - Paid Partner Content | Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused Jun 16 / Zacks.com - Paid Partner Content |
| Merck's Powerful Rally Is Coming So Back Up the Truck Jun 22 / TheStreet.com - Paid Partner Content | CEOs to Trump: You're failing Jun 15 / CNNMoney.com |
| Why You Should Add Novo Nordisk Stock to Your Portfolio Jun 22 / Zacks.com - Paid Partner Content | Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen Jun 13 / Zacks.com - Paid Partner Content |
| Glaxo's (GSK) Shingles Candidate Phase III Data Positive Jun 22 / Zacks.com - Paid Partner Content | J&J's Invokana Lowers Heart Issues, Raises Amputation Risk Jun 13 / Zacks.com - Paid Partner Content |
| Merck's Keytruda on a Roll: Can it Retain the Momentum? Jun 22 / Zacks.com - Paid Partner Content | Merck Stalls Enrolment in Two Myeloma Studies of Keytruda Jun 13 / Zacks.com - Paid Partner Content |
| Ligand Gets Milestone Payment on Partner Drug FDA Approval Jun 21 / Zacks.com - Paid Partner Content | The Zacks Analyst Blog Highlights: Facebook, Wal-Mart, Merck, Kellogg and PACCAR Jun 13 / Zacks.com - Paid Partner Content |
| VBI Vaccines Just Took a Major Step Forward in Its HBV Program Jun 21 / GuruFocus News - Paid Partner Content | New Research Reports for Facebook, Wal-Mart & Merck Jun 12 / Zacks.com - Paid Partner Content |
| Dems Roast Trump for Leaving Medicare Out of Drug Price Order Jun 21 / TheStreet.com - Paid Partner Content | Merck's Diabetes Drug Meets Primary Endpoint in Key Studies Jun 12 / Zacks.com - Paid Partner Content |
| Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion Jun 21 / Zacks.com - Paid Partner Content | Inovio's HPV Immunotherapy Moves to Phase III, Stock Rises Jun 09 / Zacks.com - Paid Partner Content |
| Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More Jun 21 / Zacks.com - Paid Partner Content | Four things to watch at the Asco cancer meeting May 30 / FT.com - Paid Partner Content |
+0.09 / +0.14%